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reducing a production of intracellular reactive
oxygen species
Sung-Gook Cho, Sang-Mi Woo and Seong-Gyu Ko*Abstract
Background: Butein has various functions in human diseases including cancer. While anti-cancer effects of butein
have been revealed, it is urgent to understand a unique role of butein against cancer. In this study, we demonstrate
that butein inhibition of reactive oxygen species (ROS) production results in suppression of breast cancer growth.
Methods: Different breast cancer cell lines were treated with butein and then subjected to cell viability and apoptosis
assays. Butein-sensitive or -resistant breast cancer cells were injected into mammary fat pads of immunocompromised
mice and then butein was injected. Breast cancer cells were categorized on the basis of butein sensitivity.
Results: Butein reduced viabilities of different breast cancer cells, while not affecting those of HER2-positive (HER2+)
HCC-1419, SKBR-3 and HCC-2218 breast cancer cells. Butein reduction of ROS levels was correlated with apoptotic cell
death. Furthermore, butein reduction of ROS level led to inhibitions of AKT phosphorylation. N-acetyl-L-cysteine (NAC),
a free radical scavenger, also reduced ROS production and AKT phosphorylation, resulting in apoptotic cell death. In
contrast, inhibitory effects of both butein and NAC on ROS production and AKT phosphorylation were not detected in
butein-resistant HER2+ HCC-1419, SKBR-3 and HCC-2218 cells. In the in vivo tumor growth assays, butein inhibited tumor
growth of butein-sensitive HER2+ BT-474 cells, while not affecting that of butein-resistant HER2+ HCC-1419 cells. Moreover,
butein inhibition of ROS production and AKT phosphorylation was confirmed by in vivo tumor growth assays.
Conclusions: Our study first reveals that butein causes breast cancer cell death by the reduction of ROS production.
Therefore, our finding provides better knowledge for butein effect on breast cancer and also suggests its treatment
option.
Keywords: Butein, Breast cancer, Reactive oxygen species, AKT, ApoptosisBackground
Butein (2′,3,4,4′- 2′,4′,3,4- or 3,4,2′,4′-tetrahydroxychal-
cone) can be isolated in various plants including Toxico-
dendron vernicifluum (Rhus verniciflua), Semecarpus
anacardium and Dalbergia odorifera, and has different
biological functions [1-8]. Butein has been known to in-
hibit cancer development or progression, while informa-
tion on its anti-cancer effect is limited in particular cell
lines or experimental conditions. Butein inhibited skin car-
cinogenesis in female CD-1 mice by inhibiting epidermal
12-lipoxygenage activity, while not affecting PKC activa-
tion [2]. Butein also induced apoptotic cell death in colon* Correspondence: epiko@khu.ac.kr
Department of Preventive Medicine, College of Korean Medicine, Kyung Hee
University, 1 Hoegi, Seoul 130701, Korea
© 2014 Cho et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.adenocarcinoma cells [9], leukemic cells [6,10], lymphoma
cells [11], multiple myeloma cells [12], breast cancer cells
[13,14], osteosarcoma cells [15], hepatocellular carcinoma
cells [16,17], prostate cancer cells [18,19], uveal melanoma
cells [20], neuroblastoma cells [21], and malignant pleural
mesothelioma cells [22]. In addition, butein inhibited cell
migration and invasion in hepatocellular carcinoma cells
[23], bladder cancer cells [24] and pancreatic and breast
cancer cells [8]. Those studies indicate that butein may
suppress both primary tumor growth and distant metasta-
ses, while most of those studies were conducted in vitro.
Meanwhile, butein inhibited glycochenodeoxycholic acid-
induced apoptosis in hepatocytes [25] and inflammatory. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Butein effect on viabilities of different breast cancer
cell lines. (A) Butein structure. (B) Butein inhibition of breast cancer
cell viabilities. Breast cancer cells were treated with different doses
of butein (0-100 μg/ml) for 48 hours and then subjected to MTT
assays. Red bars indicate 50% of cell viability. Experiments were
done in quadruplicate and repeated three times independently.
Bars indicate the mean ± SEM.
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Therefore, butein may also protect tumorigenic process.
Breast cancer is one of most common cancers. While
breast cancer is highly heterogeneous, it is broadly catego-
rized into luminal and basal subtypes on the basis of gene
expression patterns and classified into three major thera-
peutic subtypes: estrogen receptor-positive (ER+; receiving
endocrine therapy), HER2-positive (HER2+; targeting
HER2), and triple-negative (lacking expression of ER, pro-
gesterone receptor and HER2; receiving chemotherapy)
[27,28]. While anti-cancer effects of butein were reported
as mentioned above, its anti-cancer effect on breast cancer
has not been clearly proven. Butein inhibited a growth of
ER+ MCF-7 cells where aromatase was stably overexpressed
[13]. Butein also blocked CXCL12-induced migration and
invasion of HER2+ SKBR-3 cells by repressing NF-κB-
dependent CXCR4 expression [8]. In triple-negative (triple-
negative breast cancer, TNBC) MDA-MB-231 cells, butein
induced apoptosis through a generation of reactive oxygen
species (ROS) and deregulation of ERK1/2 and p38MAPK
[14]. Nevertheless, we could not rule out that butein effects
on those breast cancer cell types reflect breast cancer
subtype- or cell type-restricted or experimental condition-
specific responses, although cell lines used in literatures
above are widely used as representatives of particular breast
cancer subtypes. Thus, it is urgent to clearly understand
butein effect on breast cancer.
Butein effect on ROS generation has been investigated
in various physiological and pathological conditions
with different cell types [14,21,29-36]. While butein has
been reported to induce ROS generation in MDA-MB-
231 breast cancer cells [14], its effect on ROS gene-
ration is inconsistent in different biological conditions
[3,8,15,20,30,32]. Butein increased ROS level in particu-
lar cell types or experimental conditions, resulting in
apoptotic cell death [14,21,31]. However, butein inhibited
ROS level increased by particular environmental cues such
as ethanol, H2O2 and TNF-α [29,30,32-36]. Furthermore,
it has been revealed that ROS regulates breast cancer
progression [37,38]. Thus, butein effect on the alteration
of ROS level in breast cancer cells is still unclear.
In this study, we investigated butein effects on different
types of breast cancer cells. Our data showed that butein
caused apoptotic cell deaths of breast cancer cells, while
not affecting luminal HER2+ SKBR-3, HCC-1419 and
HCC-2218 cell lines. Furthermore, butein-induced cell
death resulted from reductions of ROS level and AKT
phosphorylation. Butein-resistant phenotype of luminal
HER2+ SKBR-3, HCC-1419 and HCC-2218 breast cancer
cell lines was due to no alteration of ROS level and AKT
phosphorylation status. Consistently, butein suppressed
in vivo breast tumor growth with the reduction of ROS
level. Therefore, our present study provides better know-
ledge for butein role against breast cancer.Methods
Reagents and cell lines
Butein was obtained from Santa Cruz Biotechnology.
Butein structure is presented in Figure 1A. Epidermal
growth factor (EGF) was purchased from R&D systems
(Minneapolis, MN, USA). N-acetyl-L-cysteine (NAC) was
obtained from Sigma-Aldrich (St. Louis, MO, USA).
MCF-10A, MCF-7, T47D, SKBR-3, MDA-MB-231 and
BT-20 cells were obtained from American Type Culture
Collection (ATCC; Manassas, VA, USA). MDA-MB-453,
BT-474, BT-20, HCC-38, Hs578T, HCC-70, HCC-1395,
HCC-1419, HCC-1569, HCC-2218 and ZR-75-1 cells were
purchased from Seoul National University Cell Bank
(Seoul, Korea). MCF-7, SKBR-3, Hs578T and MBA-MB-
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fetal bovine serum and 1% antibiotics. T47D, MDA-MB-
453, BT-20, BT-474, HCC-38, HCC-70, HCC-1419, HCC-
1569, HCC-2218 and ZR-75-1 cells were maintained in
RPMI-1640 with 10% fetal bovine serum and 1% antibiotics.
In vitro studies
For cell viability, cells were cultured in 96 well plates,
treated with different concentrations of butein, and sub-
jected to the MTT assays. Experiments were performed
in quadruplicate and repeated three times independently.
Data were presented as the mean ± SEM. P-values less
than 0.05 were considered statistically significant. Cells
were treated with butein for 24 hours and then subjected
to the Annexin V-FITC Early Apoptosis Detection Kit
(Cell Signaling, Danvers, MA, USA). Experiments were
performed by manufacturer’s recommendations and re-
peated independently three times. Data presented as the
mean ± SD. ROS levels were measured using 10 μM of
H2DCF-DA (2’,7’-dichlorofluorescin diacetate; Molecular
Probes, Eugene, OR, USA). Cells were treated with butein
for 5 minutes and then treated with H2DCF-DA for an-
other 1 hour. Flow cytometry experiments were performed
in triplicate and repeated three times independently. For
western blotting, cells were lyzed with RIPA buffer. For tis-
sue samples, tissues were homogenized and then protein
was extracted in RIPA buffer. 30 μg of protein was loaded.
Antibodies for p-SRC, p-ERK1/2, p-AKT, SRC, ERK1/2,
AKT, and actin were purchased from Cell Signaling (Dan-
vers, MA, USA). Levels of phosphorylated forms of SRC,
ERK and AKT were normalized with Actin levels in Image
J software (NIH, rsbweb.nih.gov/ij/) and levels in untreated
samples were set by 1. Data were then put in MultiExperi-
ment Viewer (MeV) software (www.tm4.org/mv.html) to
generate heat map to visualize and to analyze correlated
clusters between cell lines [39]. In brief, non-negative
matrix factorization (NMF) analysis using data for normal-
ized phosphorylation levels of SRC, ERK and AKT in dif-
ferent cell lines treated with butein or not was done in
MeV software. Rank range was 2 to 4, the highest cophe-
netic correlation value was 0.77221833, and a number of
runs were 10.
In vivo studies
For xenograft mouse tumor growth assays, 1x106 MDA-
MB-231 cells mixed with 10% matrigel (R&D Biosystems)
were injected into the 4th inguinal mammary fat pads of
nude (nu/nu) mice (the Orient, Korea). Five mice were
examined for each group. Tumor volume (V =D2xL/2;
V: volume, D: distance, L: length) and mouse weight
were measured two times a week. Butein at 10 μg/mL
or PBS was subcutaneously injected two times a week.
At day 20 post injection, mice were euthanized and tu-
mors were fixed with 4% formaldehyde. Tumor tissuesparaffin-embedded were sectioned at 10 μm and subjected
to the immunohistochemistry (IHC). Tissues were depar-
affinized and antigen was retrieved by 8 M Urea. TUNEL
assays were performed using TACS® 2 TdT DAB kit (Tre-
vigen, Gaithersburg, MD, USA). For BrdU incorporation
assays, mice were intraperitoneally injected with 300 μL of
BrdU solution (BD Pharmingen, San Diego, CA, USA) for
3 hours before being sacrificed. Anti-BrdU antibody
(AbCam, Cambridge, UK) was used in 1: 1,000 dilution.
BrdU- or TUNEL-stained cell numbers were counted in
four fields randomly chosen in tumor tissues (n = 5/
group). In addition, apoptotic cells in tumor cohorts were
observed using anti-cleaved caspase-3 antibody. Phosphor-
ylated AKT was detected using anti-pAKT antibody. To
measure ROS levels in vivo, tumor tissues were embedded
and frozen in OCT compound. Tissue sections at 20 μm
were stained with 10 μmol/L of H2DCF-DA (Molecular
Probes, Eugene, OR, USA) for 1 hour and then images were
taken by the fluorescent microscope. Fluorescent cells were
counted in four fields randomly chosen and repeated in 5
different tumor burdens. In addition, the intensity of fluor-
escence was measured at the same exposure level. Data
measured represent the mean ± SEM. Photographs are rep-
resentative images. Tumor tissues were homogenized and
lyzed with RIPA buffer. To detect phosphorylated AKT in
tumor tissues, western blots with anti-pAKT antibody and
anti-AKTantibody were performed.
Statistics
GraphPad Prism was used to test statistics (T-test or
Duncan’s post-hoc ANOVA). P-values less than 0.05 were
considered statistically significant.
Results
Butein causes apoptosis of breast cancer cells
Various breast cancer cell lines were categorized by charac-
teristics described in the previous study [27,28] were treated
with different doses of butein (1 ng/ml to 100 μg/ml) for
48 hours and then subjected to MTT assays. Butein re-
duced viabilities of almost all breast cancer cell lines
tested, whereas it did not affect viabilities of luminal
HER2+ HCC-1419, HCC-2218 and SKBR-3 breast can-
cer cells (Figure 1B).
Next, we examined butein effect on apoptosis in breast
cancer cell lines. Consistent with MTT data, butein treat-
ment for 24 hours caused cleavages of PARP and Caspases
(Caspase-8, −9 and −3) in T47D (luminal, ER+), HCC-70
(basal A, TNBC), BT-474 (luminal, ER+/PR+/HER2+) and
HCC-1569 (basal A, HER2+), while not affecting those in
luminal HER2+ HCC-1419, HCC-2218 and SKBR-3 cells
(Figure 2A). Likewise, butein at 10 μg/ml for 24 hours in-
creased Annexin V-positive and PI-positive populations in
T47D, HCC-70, BT-474 and HCC-1569 cells; whereas it
did not affect HCC-1419, HCC-2218 and SKBR-3 cells
Figure 2 Butein induction of apoptosis. (A) Breast cancer cells were treated with butein at 0-100 μg/ml (left triangles) for 24 hours and then
cleavages of PARP and Caspases were examined with appropriate antibodies in western blots. Actin was detected as a loading control. (B) Breast
cancer cells were treated with butein at 10 μg/ml for 24 hours and then stained with Annexin V and PI. Cells were then counted using flow
cytometry. Experiments were performed in triplicate and data present the mean ± SD.
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apoptosis of breast cancer cells, while luminal HER2+
HCC-1419, HCC-2218 and SKBR-3 breast cancer cells are
resistant to butein.
Butein effect on apoptotic cell death of breast cancer
cells is related with an alteration of ROS levels
Next, we examined butein effect on ROS generation in
different breast cancer cell lines. Butein at 10 μg/ml
for 5 minutes reduced ROS levels in almost all breast
cancer cell lines, whereas it did not affect those in lu-
minal HER2+ HCC-1419, HCC-2218 and SKBR-3 cells
(Figure 3A and B). Interestingly, basal ROS levels in
butein-resistant and luminal HER2+ HCC-1419, HCC-
2218 and SKBR-3 breast cancer cells were lower than
those in butein-sensitive breast cancer cells includingHER2+ BT-474 (luminal, ER+/PR+/HER2+) and HCC-1569
(basal A, HER2+) cells (Figure 3A). Overall, butein effect on
the alteration of ROS level might be one of key steps for
butein-induced apoptosis of breast cancer cells, which was
confirmed by a correlation between its reduction of ROS
levels and induction of apoptotic cell deaths (Figure 3C).
Next, we examined butein effect on cell cycle. Butein did
not commonly affect cell cycle profiles, when cells were
treated with 10 μg/ml of butein for 24 hours. Consistently,
butein caused the increase of subG1 population in different
breast cancer cells, whereas it did not accumulate luminal
HER2+ HCC-1419, HCC-2218 and SKBR-3 breast cancer
cells at subG1 phase (Figure 3D). However, butein did not
commonly affect cell cycle in different breast cancer cells
(Figure 3E). Therefore, butein effect on apoptosis appears
to be related with the alteration of ROS level.
Figure 3 Butein effects on ROS generation. (A) Butein alteration of ROS level. 100% stacked bars indicate ROS levels in the cells treated with
butein or not. Cells were treated with butein at 10 μg/ml for 5 minutes and incubated with H2DCF-DA for another 1 hour. ROS levels were
measured using flow cytometry. Experiments were independently repeated three times. Red arrows indicate ROS levels in HER2+ breast cancer
cells. (B) Representative data for butein-altered ROS levels in HER2+ breast cancer cells either sensitive (BT-474) or resistant (HCC-1419) to butein.
Negative control (Neg.) indicates no treatment of ROS indicator. Left triangles indicate the increase of ROS levels. (C) Correlations between
percentages of reduced ROS levels and percentages of apoptotic cell death. A red circle indicates butein-resistant and luminal HER2+ breast
cancer cells. (D-E) Butein effect on cell cycle profiles. Cells were treated with 10 μg/ml of butein for 24 hours and then stained with PI. Data
present the mean ± SD for altered percentages of subG1 populations in different breast cancer cells treated with 10 μg/ml of butein for 24 hours
(D). Cell populations at different stages of cell cycle were presented as 100% rate (E). Experiments were performed in triplicate.
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Next, we examined butein effects on SRC, ERK and AKT.
When cells were treated with different doses of butein for
15 minutes, butein did not uniquely affect phosphory-
lation of either SRC or ERK in different breast cancer cells
(Figure 4A), while butein inhibition of SRC has been re-
vealed [1]. However, butein inhibition of AKT phosphory-
lation was uniquely detected in various breast cancer cells
including butein-sensitive HCC-1569 (basal A, HER2+),
BT-474 (luminal, ER+/PR+/HER2+), and HCC-70 (basal A,
TNBC) cells, while it was not found in butein-resistant
and luminal HER2+ SKBR-3, HCC-1419 and HCC-2218
cells (Figure 4A and B). When we investigated patterns of
cell lines based on butein-altered phosphorylation levels of
SRC, ERK and AKT using NMF analysis, four different
clusters were hierarchically categorized (Figure 4C). Inter-
estingly, butein-resistant HER2+ SKBR-3, HCC-1419 and
HCC-2218 cell lines were clustered in the same group,
which is similar to results from butein effect on ROS re-
duction and apoptotic cell death. Thus, our data demon-
strate that butein inhibition of AKT phosphorylation is
related with apoptosis of different breast cancer cells
except for butein-resistant and luminal HER2+ HCC-1419,
HCC-2218 and SKBR-3 cells.
Next, we examined that butein inhibition of AKT phos-
phorylation was related to its reduction of ROS levels. When
butein-sensitive BT-474 cells were treated with butein at
10 μg/ml, N-acetyl-L-cystein (NAC) at 40 mM or AKT in-
hibitor, LY294002 at 10 μM for 5 minutes, LY294002 failed
to reduce ROS level, whereas butein and NAC reduced both
ROS level (Figure 4D) and AKT phosphorylation (Figure 4E).
Thus, our data indicate that butein reduction of ROS levels
leads to the decrease of AKT phosphorylation. Furthermore,
both NAC at 40 mM and LY294002 at 10 μM caused
apoptosis of HER2+ BT-474 cells (Figure 4F). To con-
firm that butein reduction of ROS production affected
cell viability by inhibiting AKT phosphorylation, butein-
sensitive and -resistant breast cancer cells were treated
with NAC or homobutein (a structural similarity between
homobutein and butein = 0.914) [40]. Whereas NAC effect
on cell viability was similar to butein, homobutein did not
affect cell viability and ROS production (Additional file 1:
Figure S1 and S2). Moreover, HER2 silencing did not alter
butein sensitivity in butein-resistant HER2+ luminal HCC-
1419 and SKBR-3 cells (Additional file 1: Figure S3), sug-
gesting that HER2 expression does not determine butein
sensitivity in HER2+ breast cancer subtype. Therefore, our
data indicate that butein inhibitions of ROS generation and
AKT phosphorylation are crucial for apoptotic cell death.
Butein inhibits ROS production and AKT phosphorylation
in vivo
Next, we examined whether butein inhibited breast cancer
growth in vivo. Butein-sensitive HER2+ BT-474 or butein-resistant HER2+ HCC-1419 cells were injected into the 4th
left mammary fat pad of nude mice, and then 10 μg/ml of
butein was subcutaneously injected two times a week.
Butein inhibited orthotopic BT-474 tumor growth,
whereas it failed to inhibit orthotopic HCC-1419 tumor
growth (Figure 5A). In addition, it did not affect body
weights (Figure 5B). Next, we examined if butein affects
tumor cell proliferation and apoptosis in vivo. BrdU-
incorporation assays showed that butein reduced BrdU-
positive tumor cell numbers in BT-474 tumor cohorts
(Figure 5C). Furthermore, butein increased cleaved caspase-
3-positive tumor cell numbers in BT-474 tumor cohorts
(Figure 5C). Therefore, our data indicate that butein inhibits
in vivo breast tumor growth by causing apoptosis.
To confirm butein effect on ROS generation and AKT
phosphorylation in vivo, levels of ROS and phosphorylated
AKT were examined in xenograft tumor tissues. Butein re-
duced ROS-producing tumor cell numbers in situ, when
DCF-fluorescent tumor cells were counted in butein-
sensitive BT-474 tumor tissues treated with either saline or
butein (Figure 5C). Therefore, butein decreases ROS level
in vivo. Likewise, butein reduced the level of phosphorylated
AKT in butein-sensitive HER2+ BT-474 cells but not in
butein-resistant HER2+ HCC-1419 cells (Figure 5C and D).
Thus, our in vivo data confirmed anti-cancer effect of butein
via reductions of ROS level and AKT phosphorylation
(Figure 6).
Discussion
Butein has long been studied in various disease model sys-
tems including cancer [3-7,9,11,13,14,18,20-22,24]. Recent
researches have revealed that butein inhibited breast can-
cer cell proliferation, migration and invasion in different
types of breast cancer cells [8,13,14]. Those previous fin-
dings suggested that butein might have diverse roles in dif-
ferent types of breast cancer cells. However, it was still
unclear whether butein effect was limited in particular
breast cancer cell lines previously examined, or could be
generalized even in certain types of breast cancer cells. So,
we examined butein effects on various breast cancer cells,
and found that common effects of butein against different
breast cancer cells.
Our data show that butein reduction of ROS level is a key
step to induce the apoptosis in various breast cancer cells.
Consistently, NAC caused apoptosis of butein-sensitive
breast cancer cells, which is in line with a previous report
that NAC prevents leukemia [41]. Thus, ROS homeostasis
is likely to be crucial for maintaining the viability even in
cancer cells. Interestingly, we found that butein effect on al-
terations of ROS levels is likely to be dependent on environ-
mental cues. In detail, when cells were treated with butein
in serum-depleted medium, ROS level was slightly and tran-
siently increased (data not shown). Therefore, butein effect
on ROS levels may be dependent on environmental cues
Figure 4 Butein effect on AKT phosphorylation. (A) Cells were treated with 10 μg/ml of butein for 15 minutes. Relative phosphorylation levels
of SRC, ERK and AKT in different breast cancer cell lines were presented in heatmap. (B) Representative data for phosphorylation levels of SRC,
ERK, and AKT. Actin was detected as a loading control. (C) NMF analysis to categorize breast cancer cells based on butein-altered phosphorylation
levels of SRC, ERK and AKT. (D-E) Cells were treated with 40 μg/ml of butein, 40 mM of NAC or 10 μM of LY294002 for 5 minutes. ROS levels were
measured by incubating cells with H2DCF-DA for another 1 hour (D), and AKT phosphorylation was detected by anti-p-AKT antibody (E). (F) Cells
were treated with NAC at 40 mM, LY294002 at 10 μM or butein at 10 μg/ml for 24 hours and then stained with Annexin V and PI. Apoptotic cells
were measured by flow cytometry.
Cho et al. Journal of Experimental & Clinical Cancer Research 2014, 33:51 Page 7 of 11
http://www.jeccr.com/content/33/1/51
Figure 5 Butein inhibition of both ROS production and AKT phosphorylation in vivo. (A) Tumor cells were orthotopically injected into
nude mice (n = 5/group). Butein (10 μg/ml) or saline was subcutaneously injected six days after orthotopic tumor injection, which was repeated
three times a week. Tumor volumes were measured at indicative time points. Asterisks indicate that P-value is less than 0.05. (B) Mouse body
weights were measured at indicative time points. (C) Histopathological observations. BrdU, cleaved Caspase-3 and pAKT were stained with
appropriate antibodies. In situ ROS was labeled with H2DCF-DA. A bar indicates a scale of 40X observation. (D) Levels of phosphorylated
and total AKT in xenograft tumor tissues.
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not find more clear procedures from previous reports that
showed a dramatic induction of ROS generation by butein
[14,31]. Those findings suggest that butein may play pleio-
tropic roles in tumor microenvironment-dependent manner.
Meanwhile, when MCF-7 cells were exposed to chronic oxi-
dative stress such as H2O2, the increased ROS level led to
their tumorigenic potentials in vitro [42]. Those data indi-
cate that ROS might have both positive and negative roles,
while it has been known to cause apoptosis. Therefore, as
we found herein, butein inhibition of ROS level is likely to
suppress cancer development.While butein has been revealed to affect SRC via direct
interactions [1], we could not find common inhibitory ef-
fects of butein on SRC or its downstream ERK in various
breast cancer cell lines. In addition, we failed to find any
common effect of butein on activities of RhoGTPases (data
not shown). Our data rather suggest that butein effect on
breast cancer cells is dependent on its inhibition of AKT
phosphorylation, while it was not found in luminal HER2+
breast cancer cell lines such as SKBR-3, HCC-1419 and
HCC-2218 cells. Our NMF analysis based on phosphoryl-
ation status of SRC, ERK and AKT also showed that
butein-resistant luminal HER2+ breast cancer cell lines
Figure 6 A cartoon to summarize butein effect on breast
cancer cells. Butein reduces intracellular ROS level, which inhibits AKT
phosphorylation. Butein inhibition of ROS production and AKT
phosphorylation results in the suppression of breast cancer growth.
While breast cancer cells tested here are sensitive to butein, luminal
HER2+ SKBR-3 and HCC-1419 and HCC-2218 cells are resistant to
butein. This resistant phenotype may be related with basal ROS level.
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fore, butein inhibition of AKT would be one of readouts
for butein sensitivity. However, our preliminary studies in-
dicate that butein inhibition of AKT phosphorylation may
be not unique in other cancer cell lines such as prostate
cancer cell lines and leukemic cell lines (unpublished data).
Therefore, butein inhibition of AKT phosphorylation is
likely to be restricted to breast cancer cells except for lu-
minal HER2+ breast cancer cells. Moreover, butein-
mediated imbalance of ROS levels resulted in the inhibition
of AKT phosphorylation. Thus, it is plausible that the cyto-
toxic effect of butein may be evoked by inhibiting ROS
production and AKT phosphorylation. Consistently, we
found that butein suppression of breast cancer growth was
correlated with its reduction of levels of both ROS and
phosphorylated AKT, in vivo. Meanwhile, butein inhibition
of AKT phosphorylation was not recovered until 24 hours
after butein treatment (data not shown), which indicate
that butein inhibition of AKT phosphorylation may be ir-
reversible. Recent studies have revealed ROS regulation of
AKT, vice versa [43,44]. Therefore, it is plausible that butein
may block a signaling circuit involving ROS and AKT to
decide cell fate. Meanwhile, homobutein failed to show
similar effects of butein on breast cancer cells, while they
are chalcone derivatives in highly similar structures and tar-
get the same molecules, HDAC and NF-κB [40]. Therefore,
butein specifically targets ROS and AKT in breast cancer
cell death, while molecular mechanisms by which butein
regulates ROS are still intriguing.Meanwhile, basal ROS levels were lower in butein-
resistant luminal HER2+ SKBR-3, HCC-1419 and HCC-
2218 breast cancer cells than in other cell lines including
HER2+ BT-474 and HCC-1569 cells, while basal ROS
levels in different breast cancer cells appeared to be inde-
pendent of breast cancer subtypes. Therefore, it is possible
that basal ROS levels may intrinsically determine butein
sensitivity. Accordingly, it is plausible that alterations of
tumor microenvironment may affect ROS levels in cancer
cells and further regulate tumor growth and metastasis
[45,46]. This notion is in line with our assumption about
different butein sensitivities of HER2+ breast cancer cells.
As ROS and AKT are involved in breast cancer metastasis
[37,47,48], environmental forces for tumor development
and metastasis may modulate ROS and AKT in cancer
cells, vice versa. Meanwhile, ROS appears to force endo-
crine therapy resistance as well as tumorigenicity in ER+
breast cancer, as glucose oxidase-mediated ROS induction
led to the phosphorylation and downregulation of ERα in
MCF-7 [42,49]. Likewise, ROS appears to regulate both
the growth and invasiveness of TNBC cells [50,51]. ROS
regulated both the migration and invasion of HER2+
SKBR-3 cells [37], which is in line with the finding that
butein inhibited SKBR-3 cell migration and invasion [8].
Thus, while our study revealed that butein failed to cause
apoptosis of luminal HER2+ breast cancer cells, it might
block metastatic abilities of those cell types. However, it is
still unclear why luminal HER2+ breast cancer cells are re-
sistant to butein and have relatively low basal ROS levels.
In our study, butein-sensitive BT-474 cells are luminal
triple-positive (HER2+, ER+ and PR+) and HCC-1569 cells
are basal A HER2+. Therefore, different subcategories of
HER2+ breast cancer cells may exhibit different butein
sensitivity, while we still do not know determinants for
those subcategories. In our study, HER2 itself did not
affect butein sensitivity, as HER2 silencing did not alter
butein sensitivity in butein-resistant HER2+ breast cancer
cells. Regarding to that issue, our ongoing study will ex-
plore to address intrinsic factors causing different butein
sensitivities associated with ROS productions in HER2+
breast cancer cells.
Conclusions
In conclusion, our study demonstrates that butein inhibits
breast cancer growth through reducing ROS level and
AKT phosphorylation. Therefore, our finding provides
better knowledge for butein effect on breast cancer and
also suggests its treatment option. Meanwhile, we failed to
find a synergistic effect of butein with one of chemothera-
peutics, doxorubicin (data not shown). However, as herbal
medicines are widely used to prevent or to treat diseases
including cancer, it is worth finding a synergism between
butein and anti-cancer drugs already known. Synergistic
effects are expected to reduce adverse effects of anti-
Cho et al. Journal of Experimental & Clinical Cancer Research 2014, 33:51 Page 10 of 11
http://www.jeccr.com/content/33/1/51cancer drugs. In addition, our study suggests that ROS
level is likely to determine characteristics of HER2+ breast
cancer cells, while these are yet defined clearly. Therefore,
this finding is also expected to improve our knowledge for
ROS biology especially in breast cancer.
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